<DOC>
	<DOCNO>NCT02538367</DOCNO>
	<brief_summary>A randomized , double-blind/open-label , placebo/active-controlled , single/multiple dose , parallel , phase 1/2a trial evaluate safety , tolerability , pharmacokinetics pharmacodynamics YH12852 healthy subject patient functional constipation</brief_summary>
	<brief_title>Phase 1/2a Trial YH12852 Healthy Subjects Patients With Functional Constipation</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<criteria>1 . Subjects must willing able provide write informed consent . 2 . BMI within range 18 25 kg/m2 . 1 . History positive serologic evidence infectious disease include HBsAg , antiHCV , antiHIV . 2 . Clinically significant lab/ECG abnormality opinion investigator . 3 . WOCBP unwilling unable use adequate contraceptive method avoid pregnancy entire study . WOCBP include female experienced menarche undergone successful surgical sterilization ( hysterectomy , bilateral tubal ligation , bilateral tubectomy , bilateral oophorectomy ) postmenopausal . Post menopause define amenorrhea â‰¥ 12 consecutive month without another cause . Clinically acceptable contraceptive method study : intrauterine device ( e.g. , loop ) , physical barrier method ( e.g. , diaphragm , uterine cap , condom ) chemical barrier method ( e.g. , spermicide ) , sterile partner , practice abstinence . 4 . WOCBP willing use hormonal method hormonereleasing device ( e.g. , mirena , implanon ) entire study . 5 . WOCBP pregnant breastfeeding . 6 . WOCBP positive pregnancy test prior randomization . 7 . Males receive vasectomy must agree use contraceptive method define ( ) refrain donate sperm throughout study . 8 . Presence uncontrolled severe medical illness . 9 . Presence disease require surgery time study .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>